To assess the effectiveness of topical tapinarof to topical betamethasone in patients with mild to moderate plaque psoriasis presenting to tertiary care hospital in Islamabad

Start Date01 Aug 2026

Sponsor / Collaborator

Pakistan Institute of Medical Sciences

NCT07352566

/ Not yet recruitingPhase 4IIT

Utilization of a Cutaneous Therapy In Situ Microdevice

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Start Date01 Aug 2026

Sponsor / Collaborator

The University of California, San Francisco

NCT07658924

/ Not yet recruitingPhase 2IIT

Evaluation of the Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma

Background:
CTCL is a rare type of non-Hodgkin lymphoma that primarily affects the skin, causing red patches, plaques, and severe itching. Currently, topical corticosteroids are commonly used for early-stage disease, but long-term application can cause significant skin side effects such as atrophy. Benvitimod is a novel, non-steroidal aryl hydrocarbon receptor (AhR) agonist. Previous studies suggest it has the potential to inhibit tumor cell proliferation and reduce skin inflammation, providing a promising new targeted therapy for CTCL patients.
Study Design:
This is a prospective, single-center, double-blind, placebo-controlled study. To ensure a highly accurate comparison and eliminate individual differences, the study uses an intra-patient (left-right) control design. Approximately 35 patients will be enrolled.
Participants will have two comparable target lesions selected on opposite sides of their body (e.g., left and right trunk or limbs). They will be randomly assigned to apply benvitimod cream to the lesion on one side and a placebo cream to the matching lesion on the other side. The creams will be applied once daily for up to 24 weeks.
Researchers will evaluate the improvement in skin lesions (using the mSWAT score), reduction in itching (using the VAS score), and closely monitor any adverse events at weeks 2, 4, 8, 16, and 24 to assess both the effectiveness and safety of the treatment.

Start Date01 Jul 2026

Sponsor / Collaborator

Peking University First Hospital

100 Clinical Results associated with Tapinarof

100 Translational Medicine associated with Tapinarof

100 Patents (Medical) associated with Tapinarof

412

Literatures (Medical) associated with Tapinarof

01 Jul 2026·JOURNAL OF ETHNOPHARMACOLOGY

Dendrobium huoshanense polysaccharides alleviate DSS-induced ulcerative colitis in mice: comparison between different parts of plant and role of GLP-1/GLP-1R axis

Article

Author: Luo, Jian-Ping ; Li, Qiang-Ming ; Zha, Xue-Qiang ; Shang, Zhen-Zi ; Zhang, Feng-Yun ; Gao, Xin

ETHNOPHARMACOLOGICAL RELEVANCE:

Dendrobium huoshanense has been long used to treat gastrointestinal disorders including ulcerative colitis (UC) in traditional Chinese medicine. Polysaccharides as its main active components can alleviate UC by reducing inflammation, and promote the secretion of glucagon-like peptide-1 (GLP-1), which possesses anti-inflammatory effects via GLP-1 receptor (GLP-1R). However, it remains unclear whether polysaccharides from different parts of this herb are equally effective in alleviating UC and whether polysaccharides function via GLP-1/GLP-1R axis.

AIM OF THE STUDY:

To identify the part in which the polysaccharide is most effective in alleviating UC and to explore its mechanism of action through GLP-1/GLP-1R axis.

MATERIALS AND METHODS:

The physicochemical properties of polysaccharides were analyzed. A dextran sulfate sodium (DSS)-induced UC mouse model was used to assess colitis-associated damage via morphological scoring, histopathological evaluation and inflammatory examination with multi-cytokine array and western blotting. Gut microbiota compositions, short-chain fatty acid contents and GLP-1 levels were measured, and their roles were checked using antibiotic mixture and GLP-1R antagonist Exendin (9-39).

RESULTS:

Stem, leaf and flower polysaccharides, with different molecular weight, monosaccharide composition and spatial conformation, differentially alleviated UC symptoms, and stem polysaccharide (DHPS) showed the strongest efficacy, as evidenced by improved epithelial integrity, mucus barrier and inflammatory disorder. DHPS-alleviated UC was independent of DHPS-altered gut microbiota and positively correlated with DHPS-elevated GLP-1 levels, which could be abolished by Exendin (9-39), suggesting that GLP-1-activated GLP-1R signaling mediated the effects of DHPS against UC.

CONCLUSIONS:

DHPS is the most effective polysaccharide for alleviating DSS-induced UC through GLP-1/GLP-1R axis, proposing DHPS is a valid candidate for UC treatment using D. huoshanense.

01 Jun 2026·EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

In Vitro Investigation of Tapinarof-Loaded Nanogels in an Imiquimod-induced HaCaT–THP-1 Co-Culture Model

Article

Author: Klusóczki, Ágnes ; Balogh, Barbara ; Fehér, Pálma ; Váradi, Judit ; Ujhelyi, Zoltán ; Pető, Ágota ; Bácskay, Ildikó

Tapinarof is a novel aryl hydrocarbon receptor (AhR) agonist that has recently been approved for the treatment of psoriasis. Although its clinical efficacy has been proven, in psoriasis, hyperkeratotic plaques and damaged barrier hinder drug penetration from conventional creams and ointments, resulting in poor bioavailability in the deeper layers of the skin. Innovative drug delivery systems can improve targeted action and reduce potential side effects. The primary goal of this study was to evaluate whether tapinarof-loaded nanogels enhance the anti-inflammatory, anti-proliferative, and anti-migratory effects of tapinarof at the cellular level using an in vitro HaCaT-THP-1 co-culture model. Initially, experiments were performed using real-time cell analysis (RTCA), and a concentration of 10 µM was found to be the most effective, showing significant cell proliferation inhibition compared to imiquimod and free tapinarof. To demonstrate cell proliferation and migration during inflammatory conditions, a wound healing assay was performed, which showed inhibited cell migration. Subsequently, the levels of inflammatory cytokines (TNF-α, IFN-γ, IL-17A, IL-23) were analyzed by ELISA, which demonstrated that tapinarof incorporated into nanogels reduced cytokine production more effectively than the drug alone. Quantitative PCR (qPCR) analysis confirmed Imiquimod (IMQ)-induced upregulation of Tnf-α and Ifn-γ, whereas Il-17a and Il-23 did not show measurable transcriptional changes under the experimental conditions. Finally, inhibition of p65 subunit nuclear translocation were observed during NF-κB pathway activation in THP-1 cells by immunofluorescence staining. Overall, our results indicate that nanogel-based delivery systems exhibit enhanced biological effects of tapinarof compared to the free drug in an in vitro psoriasis-like co-culture model, highlighting their potential as therapeutic tools for the treatment of various inflammatory skin diseases.

01 Jun 2026·CHEMICO-BIOLOGICAL INTERACTIONS

Comparative 28-day mouse study of topically applied aryl hydrocarbon receptor ligands: microbiota-derived indoles, therapeutic tapinarof, pollutants 2,3,7,8-tetrachlorodibenzo-p-dioxin and diesel exhaust particles

Article

Author: Jozwicka, Teresa ; Solanki, Subhash ; Sutter, Carrie Hayes ; Ward, Brandon ; Grice, Elizabeth A ; Slominski, Andrzej T ; Minzaghi, Deborah ; Alle, Madhusudhan ; Janjetovic, Zorica ; Thompson, Lauren L ; Tasnim, Syeda Mashnia ; Erdmańska, Patrycja ; Sutter, Thomas R

The aryl hydrocarbon receptor (AHR) regulates skin responses to microbial, therapeutic, and pollutant ligands. While AHR activation has been linked to both the etiology and treatment of skin diseases, the comparative effects of distinct ligand classes remain understudied. Here we evaluated systemic and cutaneous effects of different AHR ligands applied topically for 28 days. C57BL/6J mice were treated with microbiota-derived indole-3-pyruvic acid (IPY 1%), indole-3-aldehyde (IAld 0.01%), therapeutic, tapinarof (TAP 1%), and pollutants, 2,3,7,8-tetrachlorodibenzo-p-dioxin [TCDD 0.000003% (high) or 0.0000003% (low)] or diesel exhaust particle (DEP 0.1%). Systemic effects, skin condition and atopic dermatitis- and chloracne-like outcomes were assessed. Only high-dose TCDD resulted in minor systemic effects including early signs of hepatic injury. While DEP worsened the overall skin condition index, transepidermal water loss, ear thickness, scratching and grooming were unchanged for all chemicals. Both TAP and high-dose TCDD elevated desquamation and produced chloracne-like pathology characterized by hyperkeratosis, sebaceous gland involution and cyst-formation. TCDD caused epidermal atrophy, whereas TAP caused epidermal hyperplasia, infundibular dilatation and extended hyperkeratosis. TAP and high-dose TCDD were equally effective in increasing Cyp1a1 and Cyp1b1 mRNA, yet TAP preferentially increased Nrf2 targets, Epgn, Sprr2d, and Slpi, previously reported to drive a chloracne-like response in mice. Human keratinocytes showed similar preferential induction of EPGN and SPRR2D by TAP. These findings highlight AHR activator-specific skin effects, in part, associated with differences in selective ligand activation of modifying signaling pathways.

151

News (Medical) associated with Tapinarof

07 Jul 2026

·www.biospace.com

Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting

New analysis of pooled Phase 3 data will evaluate efficacy and safety of VTAMA cream across age groups in pediatric and adult patients with atopic dermatitis (AD) JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new analysis of Phase 3 data evaluating VTAMA cream in AD will be presented at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting, taking place July 22 – 25, 2026, in Minneapolis, Minnesota. The presentation includes a pooled post hoc analysis of data from the pivotal Phase 3 ADORING 1 and ADORING 2 clinical trials evaluating the efficacy and safety of VTAMA cream across age subgroups of pediatric and adult patients with moderate to severe AD. Details for the presentation are as follows : Abstract Title Session/Presentation Details: Tapinarof 1% Cream in Atopic Dermatitis: Consistent Efficacy Across Age Groups From Pooled ADORING Trials Thursday, July 23, 2026, 9:50-10:20 AM Central Time VTAMA cream is the only aryl hydrocarbon receptor (AhR) agonist indicated for the treatment of both plaque psoriasis in adults and AD in adults and pediatric patients ages 2 years and older. The American Academy of Dermatology (AAD) provided strong recommendations for use of VTAMA for the treatment of AD in adults and pediatric patients ages 2 years and older. 1,2 About the Phase 3 Program for VTAMA cream in Atopic Dermatitis ADORING was the Phase 3 AD clinical development program for VTAMA cream, consisting of two 8-week pivotal trials, ADORING 1 (NCT05014568) and ADORING 2 (NCT05032859), as well as ADORING 3 (NCT05142774), a 48-week, open-label, long-term extension trial. About VTAMA INDICATIONS: VTAMA ® (tapinarof) cream, 1% is an aryl hydrocarbon receptor (AhR) agonist indicated for: the topical treatment of plaque psoriasis in adults the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older SELECTED SAFETY INFORMATION Adverse Events: In plaque psoriasis, the most common adverse reactions (incidence ≥1%) were: folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza. Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain. Before prescribing VTAMA cream, please read the Prescribing Information . About Organon Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately, or differently affect women, while expanding access to essential treatments in over 140 markets. Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at and follow us on LinkedIn , Instagram , X , YouTube , TikTok , and Facebook . Cautionary Note Regarding Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Organon’s intent to present results about VTAMA as a treatment option for AD and continuing to disseminate clinically relevant data about VTAMA. Forward-looking statements may be identified by words such as “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of Organon’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the SEC, including Organon’s most recent Annual Report on Form 10-K and subsequent SEC filings, available at the SEC’s Internet site ( ). © 2026 Organon group of companies. All rights reserved. US-VTA-113380 06/26 1 Davis DMR, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in pediatric patients. J Am Acad Dermatol . Published online April 7, 2026. doi:10.1016/j.jaad.2026.02.113 2 Davis DMR, Frazer-Green L, Alikhan A, et al. Focused update: guidelines of care for the management of atopic dermatitis in adults. J Am Acad Dermatol . 2025;93(3):745.e1-745.e7. doi:10.1016/j.jaad.2025.05.1386 Contacts Media Contact: Felicia Bisaro (646) 703-1807 Investor Contact: Jennifer Halchak (201) 275-2711

18 Jun 2026

·www.globenewswire.com

Derm-Biome’s DB-006 Demonstrates Superior Efficacy in Preclinical Atopic Dermatitis Study: Reduces Itch, Inflammation, and IgE Levels, Outperforms Leading Topical Drugs

VANCOUVER, British Columbia, June 18, 2026 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc., a Vancouver-based biopharmaceutical company focused on skin health and longevity, today announced positive preclinical results for its novel small molecule, DB-006. The compound demonstrated high efficacy in treating atopic dermatitis (AD), significantly reducing key disease drivers, including pruritus (itch), epithelial thickening, inflammation, and immunoglobulin E (IgE) levels. Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition affecting up to 30% of children and 10% of adults worldwide. It is characterized by dry, scaly, intensely itchy rashes. Pruritus is the most burdensome clinical symptom, and its reduction is strongly linked to meaningful improvements in quality of life. Currently, there is no cure for AD. In a well-established preclinical model that closely replicates human AD, DB-006 significantly lowered inflammation and outperformed leading AD treatments ZORYVE® (roflumilast) and VTAMA® (tapinarof) in reducing itch symptoms, epithelial thickening, and IgE production. DB-006 has consistently demonstrated a highly favorable safety profile. Additionally, DB-006 exhibits antimicrobial activity against Staphylococcus aureus (S. aureus). Up to 90% of people with AD are colonized by this bacterium, compared to only 10–20% of the general population. S. aureus overgrowth triggers inflammation, exacerbates itching, and is a primary driver of eczema flares. Notably, most topical non-steroidal AD drugs lack this antimicrobial activity. Dr. Youwen Zhou, Chief Scientific Officer of Derm-Biome, Professor and Director of Research in the Department of Dermatology and Skin Science at the University of British Columbia: “These data are very compelling. Atopic dermatitis causes significant physical and psychological suffering for millions worldwide, and many patients still lack adequate disease control with current therapies. Our findings confirm that DB-006 has strong potential to become a best-in-class, first-line treatment candidate for mild to moderate atopic dermatitis.” Derm-Biome CEO Gordon Eberwein: “We are thrilled with these results. The prevalence of AD has increased two- to threefold, carrying a massive global burden driven disproportionately by young children. While the pipeline of expensive biologic drugs for severe AD is robust, there remains a gap in safe, effective, steroid-free topical options for mild to moderate AD. We believe DB-006 is well-positioned to fill that void.” The global AD treatment market is projected to reach $37 billion USD by 2033 (from Grand View Research published June 2026), with mild to moderate AD and topical administration representing the market’s largest segments. The topical AD market is undergoing a major shift away from traditional corticosteroids toward targeted small-molecule therapies. About Derm-Biome Pharmaceuticals, Inc Derm-Biome Pharmaceuticals, Inc. is a preclinical biopharmaceutical company dedicated to improving skin health and healthy aging. In addition to AD, DB-006 has demonstrated significant protective effects in preclinical studies of photoaging and precancerous skin conditions, suggesting that the compound may have multi-action/target effects. Mechanism of action studies are underway. Contact Investor Inquiries: Gordon Eberwein geberwein@derm-biome.com https://derm-biomepharma.com

Clinical Result

12 Jun 2026

·allsci.com

Adial Pharma buys out Stanford Uni spinout Azora, holds USD 64m financing round

Glen Allen, Virginia-based Adial Pharmaceuticals (Nasdaq: ADIL) has acquired Azora Therapeutics, a Stanford University spinout developing oral small-molecule therapies for inflammatory diseases, in an all-stock transaction accompanied by a concurrent private placement of up to USD 64 million. The deal marks a decisive pivot for Adial away from its legacy addiction therapeutics franchise toward inflammatory bowel disease, with AT177, a colon-targeted aryl hydrocarbon receptor (AhR) agonist, now the combined company’s lead program. The acquisition was structured as an asset acquisition in which all of Azora’s outstanding equity was exchanged for 437,474 shares of Adial common stock and approximately 12,930 shares of Adial Series A non-voting convertible preferred stock, representing 12,930,617 shares on an as-converted basis. No cash consideration was paid to Azora equity holders. Following stockholder approval, former Azora holders will own approximately 51% of Adial on a fully diluted basis, with pre-existing Adial stockholders retaining approximately 7.7% and private placement investors holding approximately 41.3%. The concurrent financing delivers approximately USD 32 million upfront — including conversion of outstanding notes assumed in the acquisition — through pre-funded warrants priced at USD 2.7489 per warrant. A second tranche of up to USD 32 million becomes available upon Phase I clinical study initiation, expected in mid-2027. The financing was led by Coastlands Capital with participation from Boxer Capital Management, Stonepine Capital Management, and AuGC BioFund, among others. Azora holds worldwide royalty-free rights to its technology, originating from Stanford University’s SPARK translational medicine program, and those rights transfer to Adial without geographic restriction. AT177 is a fully synthetic, patented, oral prodrug of indirubin — the most potent AhR agonist within indigo naturalis, a botanical extract with documented clinical efficacy in ulcerative colitis. Its colon-targeted formulation is designed to concentrate AhR activation at the colonic mucosa while limiting systemic exposure, addressing a key liability of earlier AhR agonist approaches: systemic AhR activation has been associated with immunosuppression and potential long-term safety risks. In preclinical studies, AT177 demonstrated robust local colonic AhR activation with markedly limited systemic drug levels and superior colon-to-systemic selectivity relative to other AhR agonists in development. The asset is currently in IND-enabling studies, with a Phase Ia/Ib proof-of-concept ulcerative colitis clinical trial planned for 2027. The AhR pathway has attracted increasing attention in inflammatory bowel disease following clinical validation of indigo naturalis in UC. Competing oral AhR agonist programs in UC include tapinarof (VTAMA), developed by Dermavant Sciences and acquired by Organon in 2024, which is the only approved AhR agonist to date. Its indications are confined to dermatology. AT177’s differentiation rests on its synthetic, gut-restricted prodrug design, which the company contends addresses the safety profile constraints that have limited systemic AhR agonists. Adial’s prior identity centered on AD04, a genetically targeted serotonin-3 receptor antagonist for alcohol use disorder. Just weeks before the Azora deal closed, Adial had submitted an application to the FDA’s Commissioner’s National Priority Voucher pilot program for AD04 and had signed a USD 60 million European licensing framework with Molteni Farmaceutici for AD04 commercialization. Those activities now represent a secondary pipeline track; the combined company’s resources and strategic focus have shifted to AT177. The effective reversal of Adial’s therapeutic identity — from a CNS-focused addiction company to an inflammatory disease developer — is underscored by the ownership structure: Azora’s former equity holders will control a majority of the combined entity post-conversion, and Azora’s co-founder Matt Davidson, PhD, assumes the role of chief development officer and joins the board. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 1License out/inAcquisitionClinical Result

100 Deals associated with Tapinarof

External Link

KEGG	Wiki	ATC	Drug Bank
-	Tapinarof	D05	DB06083

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dermatitis, Atopic	Japan	Japan Tobacco, Inc.	24 Jun 2024
Psoriasis vulgaris	Japan	Japan Tobacco, Inc.	24 Jun 2024
Plaque psoriasis	United States	Organon & Co.	23 May 2022
Psoriasis	China	Guangdong Zhonghao Pharmaceutical Co. Ltd.	29 May 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psoriasis of scalp	Phase 3	China	Shanghai Thederma Pharmaceuticals Co., Ltd.	20 Mar 2026
Dermatitis, Seborrheic	Phase 3	China	Shanghai Thederma Pharmaceuticals Co., Ltd.	27 Jun 2024
Mild Atopic Dermatitis	Phase 3	China	Guangdong Zhonghao Pharmaceutical Co. Ltd.	01 Apr 2022
Moderate Atopic Dermatitis	Phase 3	United States	Organon & Co.	01 Sep 2021
Moderate Atopic Dermatitis	Phase 3	Canada	Organon & Co.	01 Sep 2021
Severe Atopic Dermatitis	Phase 3	United States	Organon & Co.	01 Sep 2021
Severe Atopic Dermatitis	Phase 3	Canada	Organon & Co.	01 Sep 2021
Chronic large plaque psoriasis	Phase 3	-	GSK Plc	22 Jan 2018
Keratoderma, Palmoplantar	Phase 2	United States	Organon & Co.	30 Oct 2024
Pruritus	Phase 1	Japan	GSK Plc	27 Oct 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05014568 (ADORING 1, AAAAI2026)	Phase 3	Dermatitis, Atopic	654	Tapinarof cream 1%	bipgzqjjhc(mzxzlyqpoz) = wapcrdxasu mzqermoajf (gqqkfsskne ) View more	Positive	27 Feb 2026
NCT05014568 (ADORING 1, AAAAI2026)	Phase 3	Dermatitis, Atopic	654	Vehicle	bipgzqjjhc(mzxzlyqpoz) = xpbepxrtkf mzqermoajf (gqqkfsskne ) View more	Positive	27 Feb 2026
NCT05014568 \| NCT05032859 (ADORING 2, Literature) Manual	Phase 3	Dermatitis, Atopic	654	VTAMA	qrkkorhswp(vuhgxrnkvs) = pfcdhnvapi qddxixvuql (vwylhudnmm ) View more	Positive	01 Feb 2026
NCT05014568 \| NCT05032859 (ADORING 2, Literature) Manual	Phase 3	Dermatitis, Atopic	654	Vehicle	qrkkorhswp(vuhgxrnkvs) = sxtqqxjsvi qddxixvuql (vwylhudnmm ) View more	Positive	01 Feb 2026
NCT05186805 (CTgov)	Phase 2	Dermatitis, Atopic	36	Tapinarof cream, 1%	ldwzjfdwci = vgasbyiqom yrvqtfatbm (urlhtejxre, wxxgtnjhwp - vwveuxaopz) View more	-	05 Sep 2025
NCT05014568 (ADORING 1, CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	407	tapinarof cream, 1% (Tapinarof Cream)	cpdrdouevn = noajvexluv fdijnpufgp (lllxpcuari, sasqupctbj - qxlrqlnnvh) View more	-	04 Sep 2025
NCT05014568 (ADORING 1, CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	407	Vehicle cream (Vehicle Cream)	cpdrdouevn = naxhvyeaij fdijnpufgp (lllxpcuari, rqgmgcugwe - bkadeavjyh) View more	-	04 Sep 2025
NCT05032859 (DMVT-505-3102 \| ADORING 2 \| ADORING 3 \| ADORING 1, CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	406	tapinarof cream, 1% (Tapinarof Cream)	cuhwnykssj = upsfizowub vqlzlikmhw (erbjvrhbsl, wugyvcsnls - gxpqsjtrnp) View more	-	02 Sep 2025
	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	406	vehicle cream (Vehicle Cream)	cuhwnykssj = zwrvzalweg vqlzlikmhw (erbjvrhbsl, xqiqwwirgs - newgkiwchd) View more	-	02 Sep 2025
NCT05142774 \| NCT05014568 \| NCT05032859 (ADORING 3, Pubmed \| J Am Acad Dermatol)	Phase 3	Dermatitis, Atopic	728	Tapinarof cream 1%	yrwtgzkyrc(yqklmydjzj) = Most-frequent adverse events were folliculitis (12.1%), nasopharyngitis (6.9%), and upper respiratory tract infection (6.9%). hoyhbazgpv (rubjbpbhca )	Positive	01 Sep 2025
NCT05142774 (ADORING 3, CTgov)	Phase 3	Dermatitis, Atopic	728	Tapinarof cream, 1%	sbfoubslhd = jnyqdkzuuj fgbfelcrtj (urvozeuhbn, zksjhyhrjm - hndkulzqpi) View more	-	13 Aug 2025
NCT05186805 (Pubmed \| Am J Clin Dermatol)	Phase 2	Dermatitis, Atopic	36	Tapinarof Cream 1%	lejrkgwwec(leuqpwneea) = no contact dermatitis lymhksatxb (dhihlimgon ) View more	Positive	01 May 2025
NCT05142774 (ADORING 3, Company_Website) Manual	Phase 3	Dermatitis, Atopic	728	tapinarof	rawwscugrp(qwbfhlxvsb) = xpnwcubwed hvpqgkdniu (fdzwziddie ) View more	Positive	08 Mar 2025
NCT05142774 (ADORING 3, Biospace) Manual	Phase 3	Dermatitis, Atopic	728	VTAMAVTAMA cream, 1%	cgfwqssusg(mtkgqequuy) = vhcboqvxiq twrhuhlfcu (exokcxoexs ) View more	Positive	25 Oct 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis